Public Comments on Upcoming CDC ACIP Meeting Posted

I have just noticed that there are over 5,000 comments posted on the comments section of regulations.gov in the section entitled Meeting of the Advisory Committee on Immunization Practices-September 2025.

The link to the comment section is on the CDC ACIP meeting announcement web page, “Written Public Comments.”

This is the first time I’ve seen a written comment section like this for the meetings. I think it gives people a sense of what health care professionals and others think about how things are going with the current approach to preventive medicine at the CDC.

Upcoming CDC ACIP September Meeting on MMVR & Covid-19 Vaccines

The upcoming meeting on the MMVR and Covid-19 vaccines will include voting on the MMVR and Covid-19 vaccines. Usually, the committee posts the actual voting questions, which so far I have not seen on the meeting agenda. I’ll be looking for them in the next couple of days.

Here is the link to the Center for Infectious Disease and Policy (CIDRAP) at the University of Minnesota article which bears directly on the meeting topics.

CDC Advisory Committee Meeting on Vaccines Starts Tomorrow

The CDC ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) is scheduled to begin their meeting tomorrow at 10:00 AM ET despite US Senator Bill Cassidy’s recommendation that it be postponed due to concerns about the lack of experience of the committee members and because there is not yet confirmation of a new CDC Director.

In fact, the CDC Director nominee, Dr. Susan Monarez, of Wisconsin, is scheduled for her confirmation hearing at the same time as the start of the CDC ACIP meeting tomorrow morning at 10:00 AM ET. Dr. Monarez would be the first CDC director “…in decades…” (according to a report posted in The Hill in May) who has neither previously worked at the CDC “…nor obtained a Doctor of Medicine degree…”

As of this morning around 10:00 AM, the meeting agenda has not yet been finalized. So far, it looks like there will be no vote on the Covid-19 vaccine update, although there will be a vote on Thimerosal in flu vaccines about which the FDA has previously published an extensive summary.  

Procrastinate on Getting the Covid Vaccine?

This post is sort of my thinking out loud about whether or not I should get the Covid vaccine ahead of this summer that was approved last year as being appropriate to get twice a year by the CDC—once in the fall along with the flu shot and once to protect against the Covid summer surge that some experts argue has been happening every summer since the pandemic onset.

The trouble is that the dominant subvariant is no longer the JN.1 or KP.3.11. The currently dominant circulating bug is LP.8.1 according to the CDC Nowcast chart.

And what confuses me is that one expert still recommends getting the September 2023 updated vaccine, but recommends getting the “bivalent booster.”

And a recent article from the University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP) says that a preprint study (not yet peer-reviewed) says the current Covid vaccine was only 53% effective against hospitalization and 39% medically attended Covid-19. Most patients got the vaccine targeting the XBB.1.5 variant. I think that’s related somehow to the KP.2 variant. I have a vague memory of hearing about the XBB.1.5 during the CDC meeting in September 2023.

I’m a retired psychiatrist, not a retired virologist. The information available to the public seems confusing to me and I imagine I’m not the only one so affected.

The CDC is recommending the 2024-2025 Covid-19 vaccines, which target the JN.1 variant, which is now 0% of circulating variants on the list. But I’m not sure whether the current vaccines would be as protective against the different variants now dominant.

The CDC April indicators show downward trends for test positivity, ER visits, hospitalizations, and deaths.

On the other hand, an August 2024 article from Johns Hopkins warns that Covid-19 rates have consistently risen in July-August risen since 2020. The author says that it’s still unclear whether Covid-19 will continue to have dual seasonality. Other factors that affect this in addition to the emergence of more transmissible variants are human behavior, such as staying in air-conditioned spaces more and traveling.

My big question is should an old guy get the 2024-2025 Covid-19 vaccine or just wait and see, especially in light of the difficult political situation with HHS sounding like it might require new, placebo-controlled trials of some vaccines before “tweaking” them to target more current variants—which could take several months.

But it doesn’t look like there’s a plan to tweak the 2024-2025 Covid-19 vaccine in any case. I’m probably worrying too much, but I’m on the fence. I’m already too good at procrastinating.

CDC Meeting Results in Recommending a 2nd Covid-19 Vaccine Dose for Those 65yr and Older and for the Immunocompromised

I missed the October CDC meeting which resulted in a decision to recommend a 2nd dose of the Covid-19 vaccine for those 65 years and older and for the immunocompromised.

The Evidence to Recommendations (EtR) slides by Roper indicated Covid-19 circulates year round, peaking in late summer and winter.

The recommendation that those in the above-named populations should get 2 doses of Covid-19 vaccine spaced 6 months apart seems based on reasonable considerations.

It looks like the vaccine would be the same as the one previously recommended for this year.

CDC ACIP Recommendations for Covid 19 Vaccine for 2024

The CDC ACIP recommended implementation of the 2024 Covid-19 vaccine and the timeline is in the implementation slide set. CDC plans to use CDC Everything messages. Insurance plans, including Medicare, will cover the cost.

CDC Advisory Committee Makes New Recommendations for RSV Vaccine

I looked at one slide set for the Respiratory Syncitial Virus (RSV) vaccine. I didn’t watch the meeting. The ACIP Adult RSV Work Group Clinical Considerations powerpoint presentation recommend transitioning away from the shared clinical decision-making (SCDM) component for getting the RSV vaccine.

Slide 4 seems clear:

“All adults aged 75 years and older should get a single dose of RSV vaccination.

All adults aged 60-74 years and with certain chronic medical conditions or other factors that increase the risk of severe RSV disease should receive a single dose of RSV vaccination.

These recommendations would replace the SCDM recommendation, meaning that adults aged 60-74 years without risk factors for severe RSV vaccine, are no longer recommended to receive RSV vaccination.”

Stat News has a report which includes comments on the unanimous vote in favor of the above.